// App-Quantinova.ai

BSH2020‐EP‐018 : Evaluating Vyxeos use in routine clinical practice; data from the South East Scotland Cancer Network

Researchers

Presenter

  • V. Campbell

Principal Investigators

  • A. Duguid

  • N. Storrar

Medical Centers

  • Haematology, Western General Hospital, Edinburgh

  • Haematology, Victoria Hospital, Kirkcaldy, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Gastroenterology (GU)

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Neutropenic Sepsis

  • Myelodysplastic Syndrome

  • Mucositis

  • Solid malignancies

  • Sepsis

  • Chronic myelomonocytic leukemia

Biomarkers

  • Fms related tyrosine kinase 3

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Daunorubicin

  • Vidaza

  • Cytarabine liposomal

  • daunorubicin + cytarabine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved